Flow cytometric evaluation of cancer stem cell markers in HepG2 cells following sorafenib treatment
International Journal of Medical Biochemistry, cilt.4, sa.3, ss.200-204, 2021 (Scopus, TRDizin)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 4 Sayı: 3
- Basım Tarihi: 2021
- Doi Numarası: 10.14744/ijmb.2021.63935
- Dergi Adı: International Journal of Medical Biochemistry
- Derginin Tarandığı İndeksler: Scopus, TR DİZİN (ULAKBİM)
- Sayfa Sayıları: ss.200-204
- Anahtar Kelimeler: Biomarker, cancer stem cells, flow cytometry, hepatocellular cancer, sorafenib
- Açık Arşiv Koleksiyonu: AVESİS Açık Erişim Koleksiyonu
- Maltepe Üniversitesi Adresli: Evet
Özet
Objectives: Liver cancer is a leading cause of mortality. Sorafenib resistance and cancer stem cells (CSCs) are among the factors that contribute to a poor prognosis. Different drugs enrich different CSC populations with a variety of CSC markers. This study investigated the expression of CSC markers in HepG2 cells in response to low doses of sorafenib using flow cytometry. Methods: The cytotoxicity of sorafenib was determined using a cell counting kit-8 assay. The expressions of the CSC markers CD44, CD90, and CD133 were measured with flow cytometry after treatment with sorafenib for 72 hours. Results: Sofranib inhibited cell proliferation in a dose-dependent manner. Low-dose sorafenib treatment increased CD44 expression; however, there was a decrease in the expression of CD133. An increasing trend was also seen in CD90 expression, but the difference was not significant. Conclusion: The results indicate that CSC expression varied according to the sorafenib dose administered, which sup-ports the role of CSCs as novel pharmacological targets and highlights the importance of their characterization and the ability to identify them.